These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10639349)

  • 21. Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals.
    Reverdy ME; Jarraud S; Bobin-Dubreux S; Burel E; Girardo P; Lina G; Vandenesch F; Etienne J
    Clin Microbiol Infect; 2001 May; 7(5):267-72. PubMed ID: 11422254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function.
    Sakoulas G; Eliopoulos GM; Fowler VG; Moellering RC; Novick RP; Lucindo N; Yeaman MR; Bayer AS
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2687-92. PubMed ID: 15980337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of Staphylococcus aureus.
    Tascini C; Flammini S; Leonildi A; Ciullo I; Tagliaferri E; Menichetti F
    J Chemother; 2012 Aug; 24(4):187-90. PubMed ID: 23040680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multilocus sequence typing (MLST) shows that the 'Iberian' clone of methicillin-resistant Staphylococcus aureus has spread to France and acquired reduced susceptibility to teicoplanin.
    Heym B; Le Moal M; Armand-Lefevre L; Nicolas-Chanoine MH
    J Antimicrob Chemother; 2002 Sep; 50(3):323-9. PubMed ID: 12205056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prospective study of Staphylococcus aureus with reduced susceptibility to glycopeptides].
    Cantón R; Mir N; Martínez-Ferrer M; Sánchez del Saz B; Soler I; Baquero F
    Rev Esp Quimioter; 1999 Mar; 12(1):48-53. PubMed ID: 10896469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
    Betts JW; Abdul Momin HF; Phee LM; Wareham DW
    J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycopeptide susceptibility profiles of nosocomial multiresistant Staphylococcus haemolyticus isolates.
    Tabe Y; Nakamura A; Igari J
    J Infect Chemother; 2001 Sep; 7(3):142-7. PubMed ID: 11810575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of French methicillin-resistant Staphylococcus aureus isolates with decreased susceptibility or resistance to glycopeptides.
    El Solh N; Davi M; Morvan A; Damon HA; Marty N;
    J Antimicrob Chemother; 2003 Oct; 52(4):691-4. PubMed ID: 12951351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
    Felmingham D; Brown DF; Soussy CJ
    Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Searching for Staphylococcus aureus strains with reduced susceptibility to glycopeptides among clinical isolates obtained during the year of 2002].
    Młynarczyk A; Młynarczyk G; Łuczak M
    Med Dosw Mikrobiol; 2003; 55(3):209-17. PubMed ID: 14702662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) and GISA strains.
    Wootton M; Bennett PM; MacGowan AP; Walsh TR
    J Antimicrob Chemother; 2005 Nov; 56(5):944-7. PubMed ID: 16157619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-level resistance to glycopeptides amongst staphylococcus species: surveillance in a university hospital and evaluation of a vancomycin screening agar.
    Park YJ; Jun Park J; Lee SO; Oh EJ; Kee Kim B
    Diagn Microbiol Infect Dis; 2001 Nov; 41(3):155-9. PubMed ID: 11750170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
    Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
    N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycopeptide and oxacillin activity against Staphylococcus aureus isolates at a tertiary care center in Lebanon.
    Kanj SS; Ghaleb PA; Araj GF
    J Med Liban; 2004; 52(1):8-12. PubMed ID: 15881695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals.
    Ike Y; Arakawa Y; Ma X; Tatewaki K; Nagasawa M; Tomita H; Tanimoto K; Fujimoto S
    J Clin Microbiol; 2001 Dec; 39(12):4445-51. PubMed ID: 11724859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin.
    Rybak MJ; Cha R; Cheung CM; Meka VG; Kaatz GW
    Diagn Microbiol Infect Dis; 2005 Feb; 51(2):119-25. PubMed ID: 15698717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility of Brazilian staphylococcal strains to glycopeptides evaluated by different testing methods.
    Ferreira Nunes AP; Martins Teixeira L; Reis Bastos CC; de Souza Fonseca L; Netto dos Santos KR
    Curr Microbiol; 2002 Jun; 44(6):385-90. PubMed ID: 12000986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycopeptide resistance in coagulase-negative staphylococci.
    Biavasco F; Vignaroli C; Varaldo PE
    Eur J Clin Microbiol Infect Dis; 2000 Jun; 19(6):403-17. PubMed ID: 10947214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Investigation of glycopeptide resistance in methicillin resistant staphylococcal isolates].
    Hoşgör Limoncu M; Ermertcan S; Taşli H; Kurutepe S
    Mikrobiyol Bul; 2007 Oct; 41(4):511-6. PubMed ID: 18173069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.